Literature DB >> 10439055

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

E Gamelin1, M Boisdron-Celle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10439055     DOI： 10.1016/s1040-8428(98)00036-5

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  21 in total

Review 1.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.

Authors:  Hélène Blasco; Michéle Boisdron-Celle; Philippe Bougnoux; Gilles Calais; Jean-François Tournamille; Joseph Ciccolini; Elisabeth Autret-Leca; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

3.  Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.

Authors:  Rajesh R Kaldate; Abebe Haregewoin; Charles E Grier; Stephanie A Hamilton; Howard L McLeod
Journal:  Oncologist       Date:  2012-03-01

Review 4.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

5.  Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

Authors:  Jin Ho Baek; Jong Gwang Kim; Shi Nae Kim; Dong Hwan Kim; Sang Kyun Sohn; Young Jun Hong; Kyu Bo Lee
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

6.  Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

Authors:  André B P van Kuilenburg; Peter Häusler; Andreas Schalhorn; Michael W T Tanck; Johannes H Proost; Christoph Terborg; Detlev Behnke; Wolfgang Schwabe; Kati Jabschinsky; Jan Gerard Maring
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

7.  Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.

Authors:  Jiří Grim; Miloš Hroch; Hroch Miloš; Jaroslav Chládek; Chládek Jaroslav; Jiří Petera; Petera Jiří; Jiřina Martínková; Martínková Jiřina
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

8.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

9.  Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics.

Authors:  Chen-Hsi Hsieh; Yen-Ju Hsieh; Chia-Yuan Liu; Hung-Chi Tai; Yu-Chuen Huang; Pei-Wei Shueng; Le-Jung Wu; Li-Ying Wang; Tung-Hu Tsai; Yu-Jen Chen
Journal:  J Transl Med       Date:  2010-03-25       Impact factor: 5.531

10.  Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.

Authors:  Yuxiang Ma; Yuehao Lin; Benyan Zou; Wanli Liu; Yang Zhang; Liping Zhao; Yan Huang; Yunpeng Yang; Wenfeng Fang; Yuanyuan Zhao; Jin Sheng; Tao Qin; Zhihuang Hu; Salavatore J Salamone; Yunying Li; Li Zhang; Hongyun Zhao
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.